IL173483A0 - Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases - Google Patents

Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases

Info

Publication number
IL173483A0
IL173483A0 IL173483A IL17348306A IL173483A0 IL 173483 A0 IL173483 A0 IL 173483A0 IL 173483 A IL173483 A IL 173483A IL 17348306 A IL17348306 A IL 17348306A IL 173483 A0 IL173483 A0 IL 173483A0
Authority
IL
Israel
Prior art keywords
inhibitors
receptor tyrosine
tyrosine kinases
vegf receptor
quinazoline derivatives
Prior art date
Application number
IL173483A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Hennequin Laurent Francois And
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Hennequin Laurent Francois And filed Critical Astrazeneca Ab
Publication of IL173483A0 publication Critical patent/IL173483A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Manufacturing & Machinery (AREA)
  • Ceramic Engineering (AREA)
  • Diabetes (AREA)
  • Structural Engineering (AREA)
  • Endocrinology (AREA)
  • Materials Engineering (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL173483A 2003-08-06 2006-01-31 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases IL173483A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0318423.1A GB0318423D0 (en) 2003-08-06 2003-08-06 Chemical compounds
PCT/GB2004/003393 WO2005013998A1 (en) 2003-08-06 2004-08-05 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases

Publications (1)

Publication Number Publication Date
IL173483A0 true IL173483A0 (en) 2006-06-11

Family

ID=27839733

Family Applications (1)

Application Number Title Priority Date Filing Date
IL173483A IL173483A0 (en) 2003-08-06 2006-01-31 Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases

Country Status (14)

Country Link
US (1) US20070027145A1 (https=)
EP (1) EP1653965A1 (https=)
JP (1) JP2007501212A (https=)
KR (1) KR20060058781A (https=)
CN (1) CN1863534A (https=)
AU (1) AU2004262982A1 (https=)
BR (1) BRPI0413280A (https=)
CA (1) CA2534422A1 (https=)
GB (1) GB0318423D0 (https=)
IL (1) IL173483A0 (https=)
MX (1) MXPA06001394A (https=)
NO (1) NO20060641L (https=)
WO (1) WO2005013998A1 (https=)
ZA (1) ZA200601030B (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1474420T1 (sl) * 2002-02-01 2012-06-29 Astrazeneca Ab Spojine kinazolina
ATE395346T1 (de) 2003-09-16 2008-05-15 Astrazeneca Ab Chinazolinderivate als tyrosinkinaseinhibitoren
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
DE602005010824D1 (de) 2004-02-03 2008-12-18 Astrazeneca Ab Chinazolinderivate
GB0519879D0 (en) 2005-09-30 2005-11-09 Astrazeneca Ab Chemical process
US7829574B2 (en) 2008-05-09 2010-11-09 Hutchison Medipharma Enterprises Limited Substituted quinazoline compounds and their use in treating angiogenesis-related diseases
WO2010005527A1 (en) 2008-06-30 2010-01-14 Angioblast Systems, Inc. Treatment of eye diseases and excessive neovascularization using a combined therapy
JP2013514379A (ja) * 2009-12-15 2013-04-25 ニユーロツプ・インコーポレイテツド 神経障害の治療のための化合物
AR092289A1 (es) * 2011-11-14 2015-04-15 Sunshine Lake Pharma Co Ltd Derivados de aminoquinazolina y sus sales y metodos de uso
CN105330653A (zh) * 2014-08-11 2016-02-17 石药集团中奇制药技术（石家庄）有限公司 喹唑啉衍生物
US9854482B2 (en) * 2015-04-21 2017-12-26 International Business Machines Corporation Controlling a delivery of voice communications over a cellular data network or a wireless network based on user's profile
AU2017217677A1 (en) 2016-02-08 2018-07-26 Vitrisa Therapeutics, Inc. Compositions with improved intravitreal half-life and uses thereof
CN106565681B (zh) * 2016-11-10 2019-07-09 中国医学科学院放射医学研究所 含硝基咪唑基团的苯胺喹唑啉类化合物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) * 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
DE69720965T2 (de) * 1996-02-13 2004-02-05 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
NZ331191A (en) * 1996-03-05 2000-03-27 Zeneca Ltd 4-anilinoquinazoline derivatives and pharmaceutical compositions thereof
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US7262201B1 (en) * 1998-10-08 2007-08-28 Astrazeneca Ab Quinazoline derivatives
PT1154774E (pt) * 1999-02-10 2005-10-31 Astrazeneca Ab Derivados de quinazolina como inibidores de angiogenese
KR100881105B1 (ko) * 1999-11-05 2009-02-02 아스트라제네카 아베 Ｖｅｇｆ 억제제로서의 퀴나졸린 유도체
ES2267748T3 (es) * 2000-04-07 2007-03-16 Astrazeneca Ab Compuestos de quinazolina.

Also Published As

Publication number Publication date
CA2534422A1 (en) 2005-02-17
JP2007501212A (ja) 2007-01-25
US20070027145A1 (en) 2007-02-01
NO20060641L (no) 2006-05-03
KR20060058781A (ko) 2006-05-30
EP1653965A1 (en) 2006-05-10
WO2005013998A1 (en) 2005-02-17
AU2004262982A1 (en) 2005-02-17
CN1863534A (zh) 2006-11-15
GB0318423D0 (en) 2003-09-10
MXPA06001394A (es) 2006-05-19
BRPI0413280A (pt) 2006-10-10
ZA200601030B (en) 2007-05-30

Similar Documents

Publication Publication Date Title
PL1686999T3 (pl) Pochodne pirazolowe jako inhibitory receptorowych kinaz tyrozynowych
IL174261A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
IL174258A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
ZA200609427B (en) Quinazoline derivatives as erbB receptor tyrosine kinases
EP1656378A4 (en) COMPOUNDS AND COMPOSITIONS INHIBITING TYROSINE KINASE RECEPTOR ACTIVITY
IL198996A0 (en) Inhibitors of tyrosine kinases
IL173200A0 (en) Piperidyl-quinazoline derivatives as tyrosine kinase inhibitors
IL173593A0 (en) Quinazoline analogs as receptor tyrosine kinase inhibitors
IL181811A (en) Phenylaminopyrimidines are conserved in trifluoromethyl as inhibitors of @ - @ abl - @ bcr @@ kinase
IL166625A0 (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
AU2003273842A8 (en) Heterocyclically substituted indolinones and their use as receptor tyrosine kinase inhibitors
IL173483A0 (en) Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
IL184798A0 (en) Quinazoline derivatives as tyrosine kinase inhibitors
SI1562955T1 (sl) Derivati kinazolina kot inhibitorji Src-triozin kinaze
SI1660090T1 (sl) Kinazolinski analogi kot inhibitorji receptorjev tirozin kinaze
ZA200608998B (en) Imidazole derivatives as tyrosine kinase inhibitors
HK1089937A (en) Quinazoline derivatives as inhibitors of vegf receptor tyrosine kinases
HK1076745A (en) Combination of vegf receptor tyrosine kinase inhibitors for treatment of cancer
IS8386A (is) Kínasólínafleiður sem týrósínkínasatálmar
HK1102048A (en) Quinazoline derivatives as erbb receptor tyrosine kinases
HK1112903A (en) Quinazoline derivatives as tyrosine kinase inhibitors
HK1122563A (en) 4-anilino-substituted quinazoline derivatives as tyrosine kinase inhibitors
GB0621979D0 (en) Inhibitors of receptor tyrosine kinases and aurora kinases
HK1114384A (en) Quinazoline derivatives as inhibitors of egf and/or erbb2 receptor tyrosine kinase